Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider’s healthcare editor Lydia Ramsey Pflanzer and the healthcare team. Subscribe here to get this newsletter in your inbox every weekday.
Hope you all had restful weekends. Lydia Ramsey Pflanzer here with your daily dispatch of healthcare news.
Today: A look at how the pandemic changed ALS research, new data on remdesivir suggests it might not improve outcomes in COVID-19 patients, and 9 candidates that are our best short at a coronavirus treatment.
And in case you missed it: Over the weekend, the Food and Drug Administration issued an emergency use authorization for convalescent plasma for COVID-19 after feeling pressure from the White House to do so.
The coronavirus pandemic disrupted clinical trials. A top ALS researcher explains how that helps the work she’s doing.
Read the full story from Kimberly Leonard here>>
Remdesivir, the only FDA-authorized drug for COVID-19, may not significantly improve outcomes, a study found
Read the full story from Susie Neilson here>>
The world desperately needs coronavirus treatments, even if we get a vaccine. These 9 candidates are our best hope so far.
Read the full story from Aria Bendix and Andrew Dunn here>>
More stories we’re reading:
What’s on your radar going into the fall when it comes to the race for coronavirus treatments and vaccines? Let me know at firstname.lastname@example.org.
You can reach the whole team at email@example.com.
Subscribe to this newsletter here.